Summary
The supplied claims are largely unrelated to the provided FDA label excerpts and include multiple clear inaccuracies (e.g., wrong active ingredient and incorrect indication). Several non-label pharmacy coupon/discount claims are not supported by the provided prescribing information excerpts and cannot be verified.
Category Scores
Accurate Statements
Secuado is delivered as a transdermal (skin) patch.
Supported by the provided label data set for this task: Drug: SECUADO; Active ingredient: asenapine; Dosage form: transdermal system (patch).
Unsupported Statements
Savings offers for prescription drugs are common.
Not supported by the provided FDA-approved prescribing information excerpts.
Availability of Secuado savings offers changes by state.
Not supported by the provided FDA-approved prescribing information excerpts.
Availability of Secuado savings offers changes by insurer rules.
Not supported by the provided FDA-approved prescribing information excerpts.
Availability of Secuado savings offers changes by eligibility.
Not supported by the provided FDA-approved prescribing information excerpts.
Coupons and copay cards often do not apply if a person is on certain government programs (for example, some Medicaid plans or Medicare).
Not supported by the provided FDA-approved prescribing information excerpts.
Coupons and copay cards often do not apply if a person is using coverage through a plan that blocks manufacturer discounts.
Not supported by the provided FDA-approved prescribing information excerpts.
Coupons and copay cards often do not apply if a person is subject to prior authorization or formulary restrictions.
Not supported by the provided FDA-approved prescribing information excerpts.
Coupons and copay cards can be entered through a pharmacy using a copay card number (or a barcode/plan in the pharmacy system).
Not supported by the provided FDA-approved prescribing information excerpts.
Coupons and copay cards can be entered through an online redemption step before the pharmacy claim.
Not supported by the provided FDA-approved prescribing information excerpts.
The discount amount for Secuado varies widely based on the specific offer type (copay card vs. savings program).
Not supported by the provided FDA-approved prescribing information excerpts.
The discount amount for Secuado varies based on the insurer and copay.
Not supported by the provided FDA-approved prescribing information excerpts.
The discount amount for Secuado varies based on the pharmacy’s pricing.
Not supported by the provided FDA-approved prescribing information excerpts.
The discount amount for Secuado varies based on eligibility status, including whether the program allows use with the coverage.
Not supported by the provided FDA-approved prescribing information excerpts.
Contradictions
High
AI Statement
Secuado is a brand of buprenorphine.
Label Reference
Provided label data set: Active ingredient: asenapine (not buprenorphine).
High
AI Statement
Secuado is used for treatment of opioid dependence.
Label Reference
Provided label excerpts concern antipsychotic use in elderly patients with dementia-related psychosis and explicitly state SECUADO is not approved for dementia-related psychosis; no label support is provided for opioid dependence in the supplied excerpts.
Important Omissions
No mention of the boxed warning / warnings that elderly patients with dementia-related psychosis treated with antipsychotics have increased risk of death and that SECUADO is not approved for dementia-related psychosis.
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response includes major contradictions to the provided label data set (wrong active ingredient) and provides an unlabel-supported indication (opioid dependence). It also omits prominent on-label boxed warning content contained in the provided excerpts (increased mortality in elderly dementia-related psychosis; SECUADO not approved for that indication).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Multiple material inaccuracies relative to provided label information (active ingredient; indication) plus omission of boxed warning/major warning content from the provided excerpts.
Suggested Improvement
Use label-supported facts only: correct the drug identity (active ingredient) and avoid unsubstantiated indications. If discussing safety, include the label’s boxed-warning language and the explicit statement that SECUADO is not approved for dementia-related psychosis (Sections 5.1, 5.2, and 8.5 from the provided excerpts). Remove or clearly segregate non-label statements about coupons/discount mechanics, as they are not addressed in the provided prescribing information.